GlassScriptPhysician profile
Rajinder Verma
NPI 1720086812
$3,677.59
in general payments reported to CMS, 2019-2025
25 companies · $215 in 2025
The $215 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,088 · 2020: $668 · 2021: $660 · 2022: $601 · 2023: $214 · 2024: $232 · 2025: $215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $661.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $660.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $823.25 | 2019-2025 | Farxiga |
| Lilly USA, LLC | $466.80 | 2019-2025 | Mounjaro, Trulicity, Jardiance |
| Novo Nordisk INC | $340.73 | 2019-2024 | Rybelsus, Ozempic |
| Amgen INC. | $296.34 | 2019 | |
| Pfizer INC. | $290.60 | 2019-2022 | |
| Glaxosmithkline, LLC. | $263.82 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $220.64 | 2019-2021 | |
| Mylan Specialty L.P. | $198.36 | 2019-2024 | Yupelri |
| Kowa Pharmaceuticals America, INC. | $164.65 | 2019-2025 | Zoryve, Seglentis, Livalo |
| Sunovion Pharmaceuticals INC. | $127.92 | 2019 | |
| Sanofi-Aventis U.S. LLC | $100.76 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $71.45 | 2020-2022 | |
| Ultragenyx Pharmaceutical INC. | $66.66 | 2022 | |
| Genzyme Corporation | $36.14 | 2025 | |
| Abbvie INC. | $35.53 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $33.31 | 2019 | |
| Axsome Therapeutics, INC. | $28.19 | 2025 | Auvelity |
| Xeris Pharmaceuticals, INC. | $16.69 | 2025 | Gvoke Hypopen |
| Abbott Laboratories | $16.38 | 2023 | Freestyle Libre 2 |
| Medicure Pharma INC. | $15.25 | 2022 | |
| Idorsia Pharmaceuticals US INC | $14.14 | 2023 | Quviviq |
| Merck Sharp & Dohme LLC | $13.40 | 2021 | |
| Amarin Pharma, INC. | $13.01 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $12.06 | 2022 | |
| Allergan, INC. | $11.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajinder Verma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.